Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS) ML21589. 7. Juni 2015 Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Keitel, S., Hesse, T., 2015. Cancer Res 76 (4 Suppl)(P4-14-08). doi:10.1158/1538-7445.SABCS15-P4-14-08 Abstract Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry. Goebell, P., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Marschner, N., 2015. Eur Urol Suppl 14 (2)(abstract 6), e6. doi:10.1016/S1569-9056(15)60009-4… Weiterlesen Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde,… Weiterlesen